Searchable abstracts of presentations at key conferences in endocrinology

ea0077lb33 | Late Breaking | SFEBES2021

Complex management of unilateral post-Covid-19 adrenal haemorrhage during pregnancy

Yousuf Quratulain , Elhassan Yasir S , Arlt Wiebke , Jehanzeb Qazi , Krishnasamy Senthil-Kumar , Ronchi Cristina L

Background: Management of large indeterminate adrenal masses detected during pregnancy is challenging due to the risk of malignancy and the obstetric risks of surgical intervention. The spectrum of endocrine-related complications of Covid-19 is expanding. We present a case that highlights the challenging management of a large adrenal mass during pregnancy and draws attention to a rare complication of Covid-19.Case description: 26 yr-old lady presented wi...

ea0077p140 | Adrenal and Cardiovascular | SFEBES2021

Should the 1 mg -overnight dexamethasone suppression test be repeated in patients with benign adrenal incidentalomas and no overt hormone excess?

Narayanan Rengarajan Lakshmi , Knowles Gregory , Asia Miriam , Elhassan Yasir S , Arlt Wiebke , Ronchi Cristina L , Prete Alessandro

Background: Benign adrenal incidentalomas (AI) are found in 3-5% of adults. All patients should undergo a 1 mg -overnight dexamethasone suppression test (1 mg -DST) to exclude cortisol excess (non-functioning adrenal tumours, NFAT; serum cortisol ≤50 nmol/l) or diagnose possible mild autonomous cortisol secretion (MACS; serum cortisol >50 nmol/l). Current guidelines discourage repeating hormonal work-up in patients with benign AI. However, data underpinning this reco...

ea0059cc6 | Featured Clinical Cases | SFEBES2018

What lies beneath: cutaneous Kaposi’s sarcoma as a first manifestation of ectopic ACTH-dependent Cushing’s syndrome

Tresoldi Alberto S , Elhassan Yasir S , Asia Miriam , Elshafie Mona , Lane Peter , Manolopoulos Konstantinos N , Velangi Shireen S , Watkins Steven , Arlt Wiebke , O'Reilly Michael W

Introduction: Immune dysregulation is a feature of Cushing’s syndrome (CS). We report a case of CS that presented with rapidly developing cutaneous Kaposi’s sarcoma (KS).Case description: A previously well 59-year-old heterosexual man presented with a two-month history of proximal muscle weakness, recurrent mouth ulcers, and purplish skin lesions. He had a background history of hypertension. Skin biopsies were compatible with KS. History of pas...

ea0099oc3.3 | Oral Communications 3: Adrenal and Cardiovascular Endocrinology | Part I | ECE2024

Inflammation-based scores in patients with pheochromocytoma

Parazzoli Chiara , Prete Alessandro , Favero Vittoria , Aresta Carmen , Pucino Valentina , Ayuk John , Asia Miriam , Elhassan Yasir S , Chiodini Iacopo , Ronchi Cristina L

Background: Pheochromocytoma is associated with systemic inflammation, but the underlying mechanisms are unclear. Hypothesising a putative effect of catecholamines on immune cells, we investigated the relationship between plasma metanephrine levels and haematological parameters – as surrogates for systemic inflammation – in patients with pheochromocytoma. Moreover, we aimed to assess the influence of preoperative α-blockade treatment on the inflammation-based sc...

ea0075a13 | Adrenal gland | EYES2021

Adverse events associated to mitotane treatment in patients with adrenocortical carcinoma

Altieri Barbara , Detomas Mario , Kimpel Otilia , Quinkler Marcus , Canu Letizia , Mannelli Massimo , Angelousi Anna , Kaltsas Gregory , Elhassan Yasir S. , Della Casa Silvia , De Martino Maria C. , Megerle Felix , Ronchi Cristina L. , Kroiss Matthias , Fassnacht Martin

Background: Mitotane is the only drug approved for the treatment of adrenocortical carcinoma (ACC). Although adverse effects (AEs) associated to its use are frequent, detailed information are very limited. Aim was to evaluate the AEs of mitotane monotherapy in ACC patients. Methods: We performed a retrospective multicenter study including 311 ACC patients (F=200, median age 49 yrs) treated with mitotane as first line of medical treatment. Presence and grade of AEs were collect...